IMV Il valore contabile della azione
Cos'è Il valore contabile della azione di IMV?
Il valore contabile della azione di IMV, Inc. è -0.40
Qual è la definizione di Il valore contabile della azione?
Il valore contabile per azione è l'asset di una società meno le passività diviso per il numero di azioni in circolazione.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Il valore contabile della azione di aziende nel Health Care settore su TSX rispetto a IMV
Cosa fa IMV?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Aziende con il valore contabile della azione simili a IMV
- MediaAlpha ha Il valore contabile della azione di -0.40
- Conyers Park Acquisition ha Il valore contabile della azione di -0.40
- Sino International ha Il valore contabile della azione di -0.40
- Sports Ventures Acquisition ha Il valore contabile della azione di -0.40
- SearchGuy.com ha Il valore contabile della azione di -0.40
- Molecular Data Inc ha Il valore contabile della azione di -0.40
- IMV ha Il valore contabile della azione di -0.40
- Inventiva S.A ha Il valore contabile della azione di -0.40
- OptiNose Inc ha Il valore contabile della azione di -0.39
- Venus Concept ha Il valore contabile della azione di -0.39
- ParkerVision ha Il valore contabile della azione di -0.39
- Hua Lien International () ha Il valore contabile della azione di -0.39
- Phunware Inc ha Il valore contabile della azione di -0.39